WCG Podcast - The upside of monitoring during a pandemic

The upside of monitoring during a pandemic

SUMMARY KEYWORDS
monitoring, people, pandemic, clinical trial, data, study, organisations, technology, qm, rbqm, risk, site, clinical research, risk assessment, companies, focusing, industry, mcc

LINDA SULLIVAN:

There are more than 344,000 clinical trials in the United States and in more than 20 other countries. These clinical trials are all different of course, but they have one goal in common to be as productive as they can possibly be.

Welcome to episode four of CTO, the clinical trials optimization podcast. CTO is a twice monthly podcast that brings together clinical research stakeholders to exchange ideas, share knowledge, and think creatively about how to oversee, manage, and optimize clinical trial planning and execution. The podcast includes discussions with clinical research industry, thought leaders and practitioners about how the industry is transforming clinical research, design and operations to speed up the delivery of life changing therapies. I'm your host, Linda Sullivan. And I want to thank you for joining me on this exciting journey to raise the bar on clinical trials and provide an interactive forum for discussing what we do professionally every day of our lives. We hope you'll subscribe to CTO on your favorite podcast platform, so you'll automatically get every episode in your feed for free.

In this episode, we'll be talking about the automation of clinical systems and risk-based quality management. And we have just the two people you need to hear from on these issues. So let me introduce them to you. First, let's meet Duncan Hall, founder and CEO of triumph research intelligence, also known as TRI. Duncan has more than 25 years of experience as an independent consultant in the life sciences industry. During that time, his core focus has been on business process optimization, and the implementation of clinical systems to automate and drive efficiency in clinical trials. Duncan founded TRI in 2013 to specifically focus on the challenges of RBQM adoption, and as built an organisation which specializes in making an RBQM simple and accessible for all organisations, no matter how large or small. Welcome to CTO, Duncan.

DUNCAN HALL:
Thank you, Linda. Pleasure to be here.

LINDA SULLIVAN:
And now I want to bring in his colleague Rachel Oakley, Rachel is VP of RBQM services at TRI. Rachel has worked in the clinical research industry for 18 years, starting her career as a clinical trial administrator. She has served in multiple roles in clinical operations with five years spent in the functional service provision sector. Since 2015, Rachel has worked in RBQM, including creating processes roles and selecting technology to support risk assessment and central monitoring. Rachel's focuses on making RBQM as simple and effective as possible, and to work with companies to understand how to operationalize RBQM in their day to day conduct of their business. Welcome to CTO, Rachel...